TRIANA Biomedicines
Every generation of ALK inhibitors eventually meets the same wall: resistance mutations that reshape the kinase active site. TRIANA’s molecular glue degrader doesn’t try to fit into that site — it eliminates the entire ALK fusion protein, active site and all.
US-Based
Clinical-Stage
Small Molecule
Oncology
Platform
Why Highlight TRIANA Now?
TRIANA dosed its first patient in a Phase 1/2 trial of TRI-611 on March 19, 2026, and six days later received FDA Fast Track designation — marking the first molecular glue degrader designed to eliminate ALK fusion proteins to enter the clinic. Backed by $230M in equity financing and a $1.5B+ Pfizer partnership, this is a platform story that just became a clinical story.
Company Snapshot
Focus: Rational molecular glue degraders targeting undruggable oncology targets; lead program in ALK+ NSCLC
Problem: ALK TKI resistance is inevitable — compound kinase domain mutations and CNS metastases leave patients with no effective options after third-gen inhibitors like lorlatinib
Approach: Target-first molecular glue platform that systematically evaluates 600+ E3 ligases to find optimal degradation partners; AI/ML, structural biology, and bespoke chemical libraries power rational design rather than serendipitous discovery
Lead Asset: TRI-611 — oral, brain-penetrant, cereblon-recruiting molecular glue degrader of ALK fusion proteins; Phase 1/2 (first patient dosed March 2026); FDA Fast Track
Backing: $120M Series B (Dec 2025), $110M Series A (Apr 2022); Pfizer collaboration ($49M upfront + $1.5B+ milestones); total capital >$279M
Leadership: Patrick Trojer, PhD (President & CEO) — molecular glue pioneer; Caroline Germa, MD (CMO) — seasoned oncology clinical leader
Company Overview
TRIANA Biomedicines is building what may be the most systematic molecular glue discovery engine in the industry. Unlike traditional approaches that stumble onto glues through phenotypic screening or structural luck, TRIANA’s platform starts with the target protein, computationally evaluates which of the body’s 600+ E3 ubiquitin ligases is the optimal degradation partner, then launches comprehensive chemistry campaigns to find small molecules that glue the two together. The result: rational, target-first degrader design rather than serendipity.
The platform’s first clinical proof point is TRI-611, an oral ALK fusion protein degrader for NSCLC. Rather than competing for the same kinase active site that every ALK TKI targets — and that every resistance mutation reshapes — TRI-611 recruits cereblon to ubiquitinate and destroy the entire ALK fusion protein through the proteasome. It’s brain-penetrant by design, addressing the CNS metastases that affect up to 50% of ALK+ NSCLC patients even on third-generation TKIs.
Pipeline Overview
TRI-611 — ALK fusion protein molecular glue degrader in ALK+ NSCLC
First-in-human Phase 1/2 trial — first patient dosed March 2026. FDA Fast Track designation for ALK+ NSCLC after ≥2 ALK TKIs. Oral, brain-penetrant cereblon-recruiting degrader that eliminates ALK fusion proteins independent of kinase active site.
Second Development Candidate — Undisclosed oncology target
Selection of a second genomically defined molecular glue degrader candidate expected in 2026. Target and indication undisclosed.
Pfizer Collaboration — Multi-target molecular glue discovery
Strategic collaboration for novel molecular glue degraders across multiple oncology targets. $49M upfront + $1.5B+ in milestones + tiered royalties. TRIANA leads discovery; Pfizer holds exclusive option to license.
Competitive Landscape
| Company | Approach | Stage | Differentiator |
|---|---|---|---|
| TRIANA Biomedicines | Target-first molecular glue degrader (ALK via cereblon) | Phase 1/2 | 600+ E3 ligase evaluation; rational design; brain-penetrant ALK degrader; $1.5B Pfizer deal; FDA Fast Track |
| Kymera Therapeutics | Pegasus heterobifunctional degrader platform | Phase 2 | $900M+ cash; Sanofi IRAK4 deal ($2B potential); STAT6 degrader; PROTAC-focused |
| Bristol Myers Squibb | CELMoD molecular glues (mezigdomide, golcadomide) | Phase 3 | Largest molecular glue portfolio; legacy Celgene cereblon expertise; myeloma-focused |
| Monte Rosa Therapeutics | QuEEN molecular glue platform | Phase 1 | Roche + Novartis partnerships; GSPT1 and NEK7 glues; broad deal validation |
| C4 Therapeutics | TORPEDO platform (MonoDAC + BiDAC) | Phase 1/2 | CFT7455 IKZF1/3 glue in myeloma; Merck DAC partnership; dual capability |
| Pfizer (lorlatinib) | Third-generation ALK TKI (kinase inhibitor) | Approved | Current SOC; strong CNS activity; but resistance inevitable via compound mutations |
Key insight: The molecular glue space is crowded with platform stories — but TRIANA is one of the first to bring a rationally designed glue against a validated kinase-fusion oncogene into the clinic. Most competitors target transcription factors (IKZF1/3, STAT) or work with serendipity-derived scaffolds. TRIANA’s target-first approach to a resistance-defined problem (post-lorlatinib ALK+ NSCLC) sets up the cleanest proof-of-concept read for the entire field.
Market Context
The targeted protein degradation market is projected to reach $6.9 billion by 2035, with molecular glues growing at >20% CAGR. Big pharma has committed over $10 billion in biobucks to molecular glue partnerships in two years — Pfizer/TRIANA ($1.5B), Roche/Monte Rosa ($2B+), Novo Nordisk/Neomorph ($1.46B), Takeda/Degron ($1.2B), Eisai/SEED ($1.5B). Within ALK+ NSCLC specifically, lorlatinib generated ~$1.3B in 2024 sales, but resistance creates a defined clinical gap that no approved therapy currently addresses.
Potential Impact
The unlock
If TRI-611 demonstrates objective responses in post-lorlatinib ALK+ NSCLC, it validates degrading fusion oncoproteins rather than inhibiting them. That proof-of-concept has implications far beyond ALK — every kinase fusion that drives resistance (ROS1, RET, NTRK) becomes addressable through the same platform logic. TRIANA’s target-first approach, if clinically validated, transforms molecular glue discovery from an art to an engineering discipline.
For investors
TRIANA is the rare clinical-stage molecular glue company with both a validated big pharma partnership ($1.5B+ Pfizer deal) and a wholly owned lead asset entering the clinic. The Series B valued the company pre-clinical entry — clinical proof-of-concept data could drive a significant step-up at Series C or IPO. The binary event is clear: does TRI-611 shrink tumors in post-lorlatinib patients? Risk is execution: cereblon-based degradation must achieve sufficient selectivity and CNS exposure in patients.
For pharma BD
Pfizer already placed a $1.5B bet on TRIANA’s platform — but the wholly owned TRI-611 program remains unpartnered. Any pharma with an ALK or kinase-fusion franchise should be watching this Phase 1/2 closely. Early clinical data will either validate or challenge the entire rational molecular glue thesis, and the window to partner narrows once human data emerge.
TRIANA Biomedicines
| Founded | 2022 |
| Location | Lexington, MA |
| Stage | Clinical (Phase 1/2) |
| Status | Private |
| Total Funding | $230M equity + $49M Pfizer |
| Lead Investors | Ascenta, Bessemer, RA Capital, Atlas, Lightspeed |
Leadership
Key Technology
Systematically evaluates 600+ E3 ubiquitin ligases to identify optimal degradation partners for each disease target. ML algorithms rank ligases by protein surface compatibility, then bespoke chemical libraries are screened to find productive ternary complexes.
Combines high-resolution structural biology, computational proximity modeling, and DNA-encoded library screening — replacing serendipity with systematic engineering for historically undruggable targets.
Company profile generated by Biotech Voyager · Data sourced from HOUSTON Intelligence Platform, company disclosures, and public filings
